The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover

被引:19
作者
Frost, Michelle L.
Cook, Gary J. R.
Blake, Glen M.
Marsden, Paul K.
Fogelman, Ignac
机构
[1] Guys Hosp, Kings Coll London Sch Med, Osteoporosis Screening & Res Unit, London SE1 9RT, England
[2] Royal Marsden Hosp, Dept Nucl Med, Surrey, England
[3] St Thomas Hosp, Kings Coll London Sch Med, Clin PET Ctr, London, England
关键词
biochemical markers; bone mineral density; bone turnover; osteoporosis;
D O I
10.1016/j.jocd.2006.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone turnover is an important determinant of fracture risk. F-18-fluoride positron emission tomography (F-18-PET) allows the direct assessment of bone turnover at the clinically important skeletal sites such as the lumbar spine. The aim of this study was to determine if the relationship between regional bone turnover measured using F-18-PET and changes in bone mineral density (BMD) is equivalent to that seen for global skeletal measurements of biochemical markers of bone turnover. Forty-three women who had previously had an F-18-PET scan at the lumbar spine, assessment of biochemical markers of bone turnover, and a dual-energy X-ray absorptiometry scan of BMD at the lumbar spine and hip (baseline assessments) were split into 1 of 2 groups: (1) 22 women who commenced treatment for osteoporosis within 2 mo of having the baseline assessments (Treatment group); (2) 21 women who had not taken any treatments for osteoporosis since having the baseline assessments (Untreated group). Sixteen of the women in the Treatment group started risedronate therapy as part of a prospective study they were participating in, whereas the decision to treat the remaining 6 women was made by the subject's treating physician. Subjects had between 2 and 5 BMD scans over a median follow-up time of 4.1 yr to estimate the annual percentage change in BMD since baseline. The relationship between the tertiles of F-18-PET skeletal kinetic parameter K-i, reflecting regional bone turnover, and annual changes in lumbar spine and hip BMD were compared to that seen for bone formation (bone-specific alkaline phosphatase, BSALP) and bone resorption (urinary deoxypyridinoline) markers. Treated women in the highest tertile of both regional (F-18-PET) and global (biochemical markers) bone turnover showed the greatest annual percentage increases in lumbar spine BMD. The annual increase in lumbar spine BMD was 1.8%, 2.2%, and 3.2% for women in the lowest, middle, and highest tertile of BSALP, respectively, which was similar to that obtained for the regional measurement of K-i of 1.7%, 2.2%, and 2.7% respectively. Untreated women in the highest tertile of regional and global bone turnover had larger decreases in lumbar spine BMD compared to those women in the lowest tertile, with a 1.4- to 4.8-fold difference in the annual decrease in BMD between the two. Less consistent patterns were observed when assessing the relationship between regional and global bone turnover with changes in hip BMD. This study has demonstrated that the relationship between regional bone turnover measured directly at the lumbar spine with changes in BMD is similar to that seen for global skeletal bone turnover using biochemical markers.
引用
收藏
页码:46 / 54
页数:9
相关论文
共 44 条
[31]   Can biochemical markers predict bone loss at the hip and spine?: A 4-year prospective study of 141 early postmenopausal women [J].
Keen, RW ;
Nguyen, T ;
Sobnack, R ;
Perry, LA ;
Thompson, PW ;
Spector, TD .
OSTEOPOROSIS INTERNATIONAL, 1996, 6 (05) :399-406
[32]   The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Marcus, R ;
Holloway, L ;
Wells, B ;
Greendale, G ;
James, MK ;
Wasilauskas, C ;
Kelaghan, J .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) :1583-1595
[33]   Relationship of bone turnover to bone density and fractures [J].
Melton, LJ ;
Khosla, S ;
Atkinson, EJ ;
OFallon, WM ;
Riggs, BL .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (07) :1083-1091
[34]   BONE METABOLIC-ACTIVITY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND [F-18] FLUORIDE-ION IN RENAL OSTEODYSTROPHY - CORRELATION WITH BONE HISTOMORPHOMETRY [J].
MESSA, C ;
GOODMAN, WG ;
HOH, CK ;
CHOI, Y ;
NISSENSON, AR ;
SALUSKY, IB ;
PHELPS, ME ;
HAWKINS, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (04) :949-955
[35]   Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women [J].
Patel, R ;
Blake, GM ;
Rymer, J ;
Fogelman, I .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (01) :68-75
[36]  
Piert M, 2001, J NUCL MED, V42, P1091
[37]   Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study [J].
Ravn, P ;
Hosking, D ;
Thompson, D ;
Cizza, G ;
Wasnich, RD ;
McClung, M ;
Yates, AJ ;
Bjarnason, NH ;
Christiansen, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (07) :2363-2368
[38]   Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy [J].
Riggs, BL ;
Melton, LJ ;
OFallon, WM .
BONE, 1996, 18 (03) :S197-S201
[39]   BIOCHEMICAL MARKERS OF BONE TURNOVER TO MONITOR THE BONE RESPONSE TO POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY [J].
RIIS, BJ ;
OVERGAARD, K ;
CHRISTIANSEN, C .
OSTEOPOROSIS INTERNATIONAL, 1995, 5 (04) :276-280
[40]   The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation [J].
Rosen, CJ ;
Chesnut, CH ;
Mallinak, NJS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (06) :1904-1910